Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The clinical relevance of the transient intraluminal filament model of middle cerebral artery occlusion (tMCAO) has been questioned due to distinct cerebral blood flow profiles upon reperfusion between tMCAO (abrupt reperfusion) and alteplase treatment (gradual reperfusion), resulting in differing pathophysiologies. Positive results from recent endovascular thrombectomy trials, where the occluding clot is mechanically removed, could revolutionize stroke treatment. The rapid cerebral blood flow restoration in both tMCAO and endovascular thrombectomy provides clinical relevance for this pre-clinical model. Any future clinical trials of neuroprotective agents as adjuncts to endovascular thrombectomy should consider tMCAO as the model of choice to determine pre-clinical efficacy.

Original publication

DOI

10.1177/0271678X15606722

Type

Journal article

Journal

J Cereb Blood Flow Metab

Publication Date

02/2016

Volume

36

Pages

363 - 369

Keywords

Ischemic stroke, animal models, cerebral blood flow, endovascular thrombectomy, middle cerebral artery occlusion, Animals, Cerebrovascular Circulation, Disease Models, Animal, Endovascular Procedures, Humans, Infarction, Middle Cerebral Artery, Thrombectomy